Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714240 | 0.81 | TSHR (0.51) | FEN1 | |
| SCHEMBL1522723 | 0.78 | KMT2A (0.56) | FEN1ERCC5 | |
| SCHEMBL1522285 | 0.75 | ALDH1A1 (0.39) | FEN1POLB | |
| SCHEMBL1522918 | 0.74 | LMNA (0.39) | FEN1GRIK1GRIA1 | |
| SCHEMBL1523552 | 0.74 | FEN1 (0.33) | FEN1ERCC5GRIK1GRIA1 | |
| SCHEMBL1522863 | 0.72 | FEN1 (0.54) | FEN1ERCC5 | |
| SCHEMBL3538416 | 0.72 | KDM4E (0.64) | APEX1 | |
| SCHEMBL1522821 | 0.71 | ALDH1A1 (0.36) | FEN1 | |
| SCHEMBL6382759 | 0.71 | POLB (0.36) | FEN1POLBERCC5GRIK1GRIA1 | |
| SCHEMBL1271477 | 0.70 | EGLN1 (0.37) | FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058941-A1 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | TYMP, LPL, PLAT | FEN1 159/4885APEX1 1243/4885POLB 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.